FAIRFIELD, N.J., May 10, 2023 /PRNewswire/ -- Winners from the American Liver Foundation's 2023 Liver Health Poster Competition were announced today. This competition showcases posters and a brief ...
CAMBRIDGE, Mass., Oct. 11, 2023 (GLOBE NEWSWIRE) -- Omega Therapeutics, Inc. (Nasdaq: OMGA) (“Omega”), a clinical-stage biotechnology company pioneering the development of a new class of programmable ...
SAN DIEGO, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Gyre Therapeutics (“Gyre”) (NASDAQ: GYRE), a clinical-stage biotechnology company developing anti-fibrotic therapeutics for a variety of chronic liver ...
Vanoglipel (DA-1241) is a novel G-Protein-Coupled Receptor 119 (GPR119) agonist with development optionality as a standalone and/or combination therapy for both MASH and type 2 diabetes (T2D). Agonism ...
LEXINGTON, Mass.--(BUSINESS WIRE)--Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that two ...
SAN DIEGO and KALAMAZOO, Mich., March 29, 2018 /PRNewswire/ -- Cirius Therapeutics announced today that it will present a late-breaking poster describing the activity of the company's lead drug ...
“Our presentations at AASLD this year demonstrate denifanstat’s impressive ability to address advanced fibrosis in MASH patients,” said David Happel, Chief Executive Officer of Sagimet. “A secondary ...
NEW YORK, May 9, 2025 /PRNewswire/ -- American Liver Foundation (ALF) is excited to announce today the 2025 winners of their Liver Health Poster Competition. This competition showcases posters and a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results